SIC
RVNC

SJS Investment Consulting’s Revance Therapeutics, Inc. RVNC Stock Holding History

SJS Investment Consulting’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$46 – 1666
2023
Q3 		$46 Buy
+4
New +$77 ﹤0.01% 1595
2023
Q1 		– Sell
-2
Closed -$37 – 1634
2022
Q4 		$37 Buy
+2
New +$46 ﹤0.01% 1557

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SJS Investment Consulting's RVNC Position: Q4 2023 in Review

SJS Investment Consulting sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 4 shares — an estimated $46 sold.

SJS Investment Consulting first reported a position in RVNC in Q4 2022 and held it in 2 quarters. The position peaked at $46 in Q3 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • SJS Investment Consulting reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • SJS Investment Consulting sold 4 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $46.
  • SJS Investment Consulting first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
  • SJS Investment Consulting's Revance Therapeutics, Inc. position peaked at $46 in Q3 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on SJS Investment Consulting's 13F filing for Q4 2023, filed 16 Jan 2024.